Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Kura Oncology, Inc. | kura-10k_20171231.htm |
| EX-32.1 - EX-32.1 - Kura Oncology, Inc. | kura-ex321_6.htm |
| EX-31.2 - EX-31.2 - Kura Oncology, Inc. | kura-ex312_10.htm |
| EX-31.1 - EX-31.1 - Kura Oncology, Inc. | kura-ex311_12.htm |
| EX-23.1 - EX-23.1 - Kura Oncology, Inc. | kura-ex231_8.htm |
| EX-10.24 - EX-10.24 - Kura Oncology, Inc. | kura-ex1024_450.htm |
| EX-10.10 - EX-10.10 - Kura Oncology, Inc. | kura-ex1010_616.htm |
Exhibit 10.23
***Text Omitted and Filed Separately with the Securities and Exchange Commission.
Confidential Treatment Requested Under
17 C.F.R. Sections 200.80(b)(4) and 240.24b-2
VIA CERTIFIED MAIL
August 24, 2017
The Regents of the University of Michigan
Office of Research and Sponsored Projects
3003 S. State St. Room 1070
Ann Arbor, MI 48109-1274
Attn: Anthony L. Neilsen, J.D.
|
RE: |
Research Agreement between Kura Oncology, Inc. (“Kura”) and The Regents of the University of Michigan (the “University”) dated February 15, 2015 (the “Research Agreement”) |
|
(Amendment 6 to the Patent License Agreement dated December 22, 2014) |
Dear Anthony:
Pursuant to Section 8.2 of the Research Agreement, we hereby give notice of the exercise by Kura of its option to obtain an exclusive royalty-bearing license to the University’s interest in the patent application numbered […***…]. Effective upon this notice, the Patent License Agreement between the University and Kura is deemed amended (Amendment 6) to add the above-referenced patent application to subsection (ii)(a) of the definition of PATENT RIGHTS under such agreement.
Please let me know if you have any questions.
Sincerely,
/s/ Annette North
Annette North
SVP, General Counsel
cc: Ed Pagani, Ph.D., Associate Director,
University of Michigan
***Confidential Treatment Requested
3033 Science Park Road, Suite 220, San Diego, CA 92121